secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2026-02-06T23:59:59+00:00
Accession:  0001635088-26-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant reports positive Phase 2 brepocitinib data in CS; Q3 loss $313.7M vs $208.9M
--------------------------------------------------------------------------------

- Phase 2 BEACON study: brepocitinib 45mg achieved 22.3-point CSAMI-A improvement vs 0.7 placebo (Δ21.6, p<0.0001).
- NDA submitted to FDA for brepocitinib in dermatomyositis; Phase 3 CS study planned for 2026.
- Q3 loss from continuing ops $313.7M ($0.38/share) vs $208.9M ($0.22); revenue fell to $2M from $9M.
- Cash and marketable securities of $4.5B as of Dec 31, 2025; R&D expenses rose to $165.4M.
- Immunovant's IMVT-1402 D2T RA trial fully enrolled; Genevant jury trial set for Mar 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000163508826000009/0001635088-26-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000163508826000009/roiv-20260206.htm
  HTML page:      https://secwatch.observer/filing/0001635088-26-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer